IFNAR1 and infection: Once the challenge infection of IFNAR −/− mice with AHSV-4 had been characterised and that doses in the order of 106 pfu/mouse induced clinical signs, viraemia and significant levels of lethality, we evaluated the protective efficacy of a recombinant MVA expressing VP2 of AHSV-4 (MVA-VP2).